Skip to main content

Table 4 (Mean ± SD) months of follow-up to outcome normalization in the 78 patients with DAS28-SR and the 63 patients with B-SR

From: Patient’s perspective of sustained remission in rheumatoid arthritis

Outcome, (N° of patients who achieved norm in DAS28-SR/B-SR patients)

Months of follow-up to outcome normalization in 78 DAS28-SR patientsa

Months of follow-up to outcome normalization in 63 B-SR patientsa

ESR-N, (77/61)

1.5 ± 3

2 ± 4

CRP-N, (73/63)

2.9 ± 4.4

2.4 ± 3.7

HAQ-N, (75/63)

6 ± 5.1

4.8 ± 4.2

PVAS-N, (77/63)

6.1 ± 4.6

4.8 ± 3.2

OVAS-N, (76/63)

6.1 ± 4.7

4.9 ± 3.4

SF-36-N, mental component, (67/54)

6.2 ± 4.7

5.6 ± 4.3

SF-36-N, physical component, (60/48)

7 ± 5.5

5 ± 3.3

Tender joint count ≤1(0–68 joints), (76/63)

7.6 ± 4.9

7 ± 4.5

Swollen joint count ≤1 (0–66 joints), (72/63)

7.7 ± 4.8

7.7 ± 4.9

Physician overall disease ≤10 (0-100 mm), (77/63)

8.6 ± 4.4

8.1 ± 4.6

Absence of substantial fatigue, (34/24)

8.7 ± 5.4

6.4 ± 4.3

  1. N° = Number. DAS28-SR = Sustained remission according to the Disease activity index (28 joints considered). B-SR = Boolean sustained remission. ESR-N = Erythrocyte sedimentation rate within norms. CRP-N = C-reactive protein within norms. HAQ-N = Health assessment questionnaire within norms. P-VAS-N = Pain visual analogue scale within norms. O-VAS-N = Overall disease-visual analogue scale within norms. SF-36-N = Short-Form 36v2 survey within norms
  2. aData presented as (mean ± SD)